title: Antibody to hepatitis C (anti C 100-3) in French hemophiliacs.
abstract: 486 patients followed in four French hemophilia centres were tested for antibody to hepatitis C virus C100-3 recombinant protein. On samples collected in 1989, the overall incidence of anti-C 100-3 positivity was 66%. None of the 27 patients only exposed to solvent-detergent treated factor VIII or IX concentrates had C 100-3 antibodies. There was no difference according to the type of hemophilia nor to its severity. Serological follow-up from 1985 to 1989 was carried out on 51 patients. Two third of the C-100 3 paradoxically seronegative patients in 1989 were in fact positive for these antibodies within the last 5 years. They have lost their HCV antibodies as seen with the presently available C 100-3 test. Actually, as the virus has been already present at least for the last 10 years, (on 51 samples collected in 1979, the incidence of C-100-3 positivity was 78%), all treated patients may well have been in contact with HCV.
authors.affiliation: Centre d'Hématologie et de Transfusion Sanguine de Versailles, Le Chesnay, France.
authors.forename: P
authors.initials: P
authors.lastname: Maisonneuve
authors.forename: Y
authors.initials: Y
authors.lastname: Laurian
authors.forename: C
authors.initials: C
authors.lastname: Guerois
authors.forename: F
authors.initials: F
authors.lastname: Verroust
authors.forename: F
authors.initials: F
authors.lastname: Ferrer Le Coeur
authors.forename: A M
authors.initials: AM
authors.lastname: Couroucé
authors.forename: L
authors.initials: L
authors.lastname: Noel
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000410:Alanine Transaminase / Q000097:blood; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005164:Factor IX / Q000302:isolation & purification / Q000592:standards / Q000627:therapeutic use; D005169:Factor VIII / Q000302:isolation & purification / Q000592:standards / Q000627:therapeutic use; D005602:France / Q000453:epidemiology; D015658:HIV Infections / Q000150:complications / Q000453:epidemiology / Q000635:transmission; D015528:HIV Seroprevalence; D006467:Hemophilia A / Q000150:complications* / Q000628:therapy; D002836:Hemophilia B / Q000150:complications* / Q000628:therapy; D006508:Hepatitis Antibodies / Q000032:analysis*; D006509:Hepatitis B / Q000150:complications / Q000453:epidemiology / Q000635:transmission; D006526:Hepatitis C / Q000150:complications / Q000201:enzymology / Q000453:epidemiology* / Q000276:immunology / Q000635:transmission; D018937:Hepatitis C Antibodies; D006801:Humans; D015994:Incidence; D007223:Infant; D008875:Middle Aged; D015995:Prevalence
chemical_list: D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies; C078224:anti-C100-3; D005169:Factor VIII; D005164:Factor IX; D000410:Alanine Transaminase